Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...

Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...

Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to remove 114 positions as ...

As geopolitics bring reshoring interest to a fever pitch, the United States Pharmacopeia (USP) is adding to the impetus for ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...